Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Tekla Life Sciences Investors HQL NYSE

NYSE • Financial Services • Asset Management • US • USD

SharesGrow Score
89/100
4/6 Pass
SharesGrow Intrinsic Value
$86.78
+388.9%

Tekla Life Sciences Investors (HQL) is a Asset Management company in the Financial Services sector, currently trading at $17.75. It has a SharesGrow Score of 86/100, indicating a strong investment profile with 4 out of 7 criteria passed.

SharesGrow calculates the intrinsic value of HQL = $86.78 (+388.9% from the current price, the stock appears undervalued).

Valuation: HQL trades at a trailing Price-to-Earnings (P/E) of 5.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.

Financials: revenue is $86M, +134.1%/yr average growth. Net income is $86M, growing at +134.4%/yr. Net profit margin is 99.1% (strong). Gross margin is 100% (+22.3 pp trend).

Balance sheet: total debt is $0 against $514M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.74 (strong liquidity). Debt-to-assets is 0%. Total assets: $515M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 56/100 (Partial), Future ?/100 (Fail), Income 100/100 (Pass).

HQL SharesGrow Score Overview

89/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 75/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 56/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HQL

✓
VALUE Pass
100/100
HQL trades at a trailing Price-to-Earnings (P/E) of 5.8 (S&P 500 average ~25). Forward PEG 0.01 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.01. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
HQL: +134.1%/yr revenue is, +134.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
75/100
HQL: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet HQL: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.74 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
56/100
HQL: Gross margin is 100% (+22.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 56/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✓
INCOME Pass
100/100
HQL: Net profit margin is 99.1%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range10.55-17.8
Volume147.27K
Avg Volume (30D)132.32K
Market Cap$512.49M
Beta (1Y)0.74
Dividend Yield$1.9100
Share Statistics
EPS (TTM)2.96
Shares Outstanding$28.87M
IPO Date1992-05-01
CEODaniel R. Omstead
Financial Highlights & Ratios
Revenue (TTM)$86.39M
Gross Profit$86.39M
EBITDA$85.59M
Net Income$85.59M
Operating Income$85.59M
Total Cash$75.54K
Net Debt$-75.54K
Total Assets$515.38M
Price / Earnings (P/E)6
Price / Sales (P/S)5.93
Analyst Forecast
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS87911K1007

Price Chart

Track all markets on TradingView
HQL
Tekla Life Sciences Investors ↗  ·  NYSE
Financial Services • Asset Management
10.55 52WK RANGE 17.80

People Also View

UTF
UTF
Cohen & Steers Infrastructure Fund, Inc
$26.48
-0.86%
 RVT
RVT
Royce Value Trust Inc.
$18.13
+1.17%
 EVT
EVT
Eaton Vance Tax-Advantaged Dividend Income Fund
$25.73
+0.94%
 ETG
ETG
Eaton Vance Tax-Advantaged Global Dividend Income Fund
$21.85
+1.49%
 FPF
FPF
First Trust Intermediate Duration Preferred & Income Fund
$18.38
+1.16%
 HQH
HQH
Tekla Healthcare Investors
$19.76
+1.96%
 RNP
RNP
Cohen & Steers REIT and Preferred Income Fund, Inc.
$20.66
-0.65%
 FFC
FFC
Flaherty & Crumrine Preferred Securities Income Fund Inc.
$16.02
+0.25%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message